Xeris Biopharma

About:

Xeris Biopharma is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.

Website: http://xerispharma.com

Twitter/X: xerispharma

Top Investors: Deerfield, Redmile Group, Silicon Valley Bank, Asahi Kasei, Mérieux Equity Partners

Description:

Xeris Biopharma is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.